9 March, 2021
The third year of iPC project has started and in order to present the current work that each consortium partner is developing, we asked them to summarize the processes that are being done behind the project. This week we start with the Ludwig Maximilian University of Munich where Prof. Dr. Roland Kappler explains the current work that they are developing within iPC:
“Within task 9.3, LMU is responsible for the validation of treatment response predictions with preclinical models. We are currently using a streamlined workflow for multiple cell-based applications in fluorescence imaging and high-content analysis to monitor the first predicted compounds for their effect in classical and PDX-derived liver tumor cell lines.”
